Metagenomi Therapeutics (MGX) TD Cowen 46th Annual Health Care Conference summary

Strategic focus and pipeline prioritization

• Rebranded to reflect evolution into a clinical-stage company, prioritizing capital allocation to advance lead program MGX-001 for hemophilia A and leveraging its approach for additional programs.

• Achieved proof-of-concept data for MGX-001, demonstrating best-in-class potential as a curative one-time treatment for hemophilia A.

• Internal pipeline includes preclinical validation for antithrombin III deficiency and ongoing collaborations, notably with Ionis, targeting cardiometabolic indications.

• Strategic partnerships, such as with Ionis, are key to unlocking long-term value and accelerating development.

• Capital reallocation extended financial runway into Q4 2027, with $184 million in cash at last quarter's end.

Clinical development and regulatory plans

• MGX-001 demonstrated normalized and durable Factor VIII activity in non-human primate studies, with no thrombosis risk at high doses.

• IND submission for MGX-001 planned for Q4, with a global first-in-human single-arm Phase I/II study to establish safety and optimal dosing.

• Durability data will be included in registrational studies, and manufacturing is already at pivotal scale.

• Initial clinical focus on adults, with rapid expansion to pediatric patients due to high unmet need and potential for lifelong benefit.

• Off-target editing risks addressed using three orthogonal methods, with no detectable off-target effects observed.

Market positioning and future outlook

• Aims to provide a durable, one-time cure for hemophilia A, addressing high lifetime treatment costs and significant healthcare burden.

• Early engagement with key opinion leaders, patient advocacy groups, and payers to prepare the market for gene-edited therapies.

• Differentiation from gene therapy products by offering permanent gene integration and a favorable safety profile.

• Ongoing business development to explore additional partnerships and expand the application of proprietary gene-editing technologies.

• Plans to disclose initial clinical data after IND submission, with rapid efficacy observed in preclinical models.